Clinical trial NCT05071430: Safety and Efficacy of HB-1 for Panic Disorder
Official title: Safety and Efficacy of HB-1 for Panic Disorder: A Multicenter, Randomized, Double Blind, Placebo-Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Panic Disorder
Keywords: panic
mental illness
Lead sponsor: Honeybrains Biotech LLC
Sponsor class: INDUSTRY
Collaborators: name: Cognitive Research Corporation
First posted: 2021-10-08
Enrollment: 86
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: A sample size of 80 patients is planned for the study to be randomized in a 1:1 ratio of active to control.
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the safety and efficacy of potential new treatment called "HB-1" versus placebo in male and female adult patients aged 18 to 60 years, inclusive, with panic disorder.

Detailed description: This is a multicenter, randomized, double-blind, placebo-controlled trial. All patients with panic disorder, with or without specified co-morbidities, who meet all of the inclusion and none of the exclusion criteria will be eligible. Patients and researchers will be blinded to their treatment group.

The study will enroll approximately 80 adult patients who meet the diagnosis of panic disorder.

The patients will be treated for 12 weeks including a 1 week safety follow up visit following the last dose of study drug.

Eligibility criteria: * Inclusion Criteria

  1. Male or female aged 18 to 60 years old, inclusive, at the time of informed consent.
  2. Meets Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Criteria for Panic Disorder.
  3. Documented moderate to severe levels of symptoms at baseline (Panic Disorder Severity Scale of 13 or above)
  4. Medically stable on current medication regimen for at least 3 months including PRN ('as needed') medications as determined by Investigator.
  5. Willing to remain on current doses of other psychiatric medications throughout the length of the trial (unless a dose reduction is warranted due to improvement in symptoms).
  6. Willing and able to safely stop any of the following medications prior to study trial: Inhibitors or inducers of CYP3A4 (erythromycin, ritonavir, telithromycin, rifampin), HMG-CoA (hydroxy methylglutaric acid coagulase) Reductase Inhibitors (Simvastatin, Lovastatin, Atorvastatin), Beta Blockers (Timolol eyedrops, Metoprolol), Neuromuscular Blocking Agents (curare-like and depolarizing), Antihypertensive Agents (Prazosin and vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta blockers), Inhalation Anesthetics, Disopyramide, Flecainide, Quinidine, Cimetidine, Lithium, Carbamazepine, Phenobarbital, Cyclosporine, Digitalis, Aliskiren, Ramipril and Ramiprilat, aspirin.
  7. Fluent in English.
  8. Willing to take HB-1 or placebo.
  9. Willing and able to provide informed consent indicating an understanding of the requirements of the study and a willingness to comply with scheduled visits and all study procedures.
  10. Female patients must be surgically sterile (or have a monogamous partner who is surgically sterile) or be least 2 years postmenopausal or commits to use 2 acceptable forms of birth control (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, any form of hormonal contraceptives, or abstinence) for the duration of the study and for 4 months following the last dose of study treatment. Male patients must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study and for 4 months following the last dose of study treatment. Individuals who are involved exclusively in same-sex relationships are exempt from the birth control requirements but must agree to abide by the recommendations if they do engage in a heterosexual relationship.
  11. Female patients who are women of childbearing potential (WOCBP) must have a negative pregnancy test at Screening, within 7 days of dosing with study treatment.
* Exclusion Criteria:

  1. Severe uncontrolled cardiac disease within 6 months of Screening, including but not limited to uncontrolled hypertension, hypotension (defined as below 90/60); unstable angina; myocardial infarction (MI) or cerebrovascular accident (CVA).
  2. Any clinically significant electrocardiogram (ECG) abnormalities at screening.
  3. Inadequate hepatic function defined as total bilirubin \>1.5 × the upper limit of normal (ULN) ranges of each institution, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \>3 × the ULN range of each institution.
  4. Inadequate renal function defined as serum creatinine \>1.5 × the ULN range of each institution and/or estimated glomerular filtration rate (eGFR) \<60.
  5. Any clinically significant abnormalities in clinical laboratory assessments as assessed by the Investigator.
  6. Any other systemic conditions or organ abnormalities that in the opinion of the Investigator may interfere with the conduct and/or interpretation of the current study.
  7. Unable to complete neuropsychological testing.
  8. Diagnosis of Bipolar I, Bipolar II disorder or Schizophrenia.
  9. History of suicidal behaviors including ideation.
  10. Current treatment with doses of benzodiazepines that are outside the FDA-approved prescriber's information.
  11. Already on treatment with either telmisartan or verapamil or both.
  12. Documented prior drug allergy to either telmisartan or verapamil.
  13. Documented contraindication to taking telmisartan or verapamil: (eg, Duchenne's muscular dystrophy, myasthenia gravis).
  14. Documented moderate to severe substance abuse within the last 6 months (recreational cannabis use is allowed).
  15. Pregnant or breastfeeding.

Primary outcomes:
measure: Incidence of Treatment-Emergent Adverse Events
timeFrame: Up to 12 weeks
measure: Change in Panic Disorder Symptom Severity Scale (PDSS)
timeFrame: Up to 12 weeks
measure: Change in Clinical Global Impression-Severity Scale (CGI-S)
timeFrame: Up to 12 weeks
Secondary outcomes:
measure: Number of Panic Attacks
timeFrame: Up to 12 weeks
Other outcomes:
Locations:
city: Garden Grove
country: United States
facility: Collaborative Neuroscience Research
state: California
city: San Jose
country: United States
facility: Lumos Psychiatric Services
state: California
city: Hartford
country: United States
facility: Institute of Living
state: Connecticut
city: Jacksonville
country: United States
facility: CNS Healthcare
state: Florida
city: Orlando
country: United States
facility: CNS Healthcare
state: Florida
city: Chicago
country: United States
facility: Uptown Research Institute
state: Illinois
city: Berlin
country: United States
facility: Hassman Research Institute
state: New Jersey
city: Brooklyn
country: United States
facility: SPRI Clinical Trials
state: New York
city: Staten Island
country: United States
facility: Richmond Behavioral Associates
state: New York
city: Memphis
country: United States
facility: CNS Healthcare
state: Tennessee
Study officials:
affiliation: Collaborative NeuroScience Research, Garden Grove, CA
name: David Walling
role: PRINCIPAL_INVESTIGATOR
References: